Research and development - Today Stories

Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“ REHOVOT, Israel and HEIDELBERG, Germany, February 20, 2024. AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel. AION Labs’ next startup will focus on the developm…

New Thermo Scientific Dionex Inuvion Ion Chromatography System streamlines ion analysis and expands analytical testing capabilities for ionic and small polar compounds WALTHAM, Mass.--(BUSINESS WIRE)-- To support a wider range of ion chromatography analysis with one instrument, Thermo Fisher Scientific Inc., today launched the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis. beverage labs with the necessary equipment to determine ionic contaminants in water. The technology also helps ident…

The team will engineer cells to make membrane proteins efficiently The proteins will be used for drug discovery and screening, and as catalysts in sustainable chemical production The £1.8m Engineering Biology Mission Award has been given by UK Research and Innovation (UKRI) A team of academics from Aston University and the University of Warwick has secured a £1.8m grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. Membrane proteins are crucial molecules on the surface of cells with numerous biological functions, such as sensing hormones or cell communication. The top ten selling medicines worldwide and multiple vaccines, including those for COVID-19, hepatitis B and whooping cough, target m…

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group)…

Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies  New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes  Cambridge, UK, 22nd January 2024: Sano Genetics, a software company accelerating precision medicine research, has raised $11.4 mill…

Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations CARLSBAD, Calif.--(BUSINESS WIRE)-- Earlier this year, scientists unveiled the first draft of the pangenome, based on full genetic blueprints from 47 people around the world to create a more diverse representation of the human genome1. To more accurately account for this richer picture of human genomic variation, Thermo Fisher Scientific has launched the new Axiom™ PangenomiX Array*, its largest and most ethnically diverse array to date, offering optimal genetic coverage for population scale disease studies and pharmacogenomic research. This press release features multimedia. View the full release here: https://www…

Calibre Scientific has acquired LineaLAB, SL, a distributor of analytical, bio and laboratory equipment based in Badalona (Barcelona), Spain. LineaLAB is Calibre Scientific’s fourth acquisition in Spain and further bolsters its presence in the Iberian Peninsula. 50.9% of the shares in LineaLAB, SL were sold by the family of the company's late founder and former managing director, Sebastián Estrades. Brand Group has sold its 49.1% stake in LineaLAB. Divestment serves to focus on Brand Group's core businesses. BARCELONA, Spain and FRANKFURT AM MAIN, Germany and LOS ANGELES, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific has acquired LineaLAB, SL, a provider of analytical, bio and laboratory equipment based in Badalona (Barcelona). LineaLAB is Calibre Scientific’s fourth acquisition i…

A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. Heidelberg, November 7, 2023. BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease. Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that produce antibodies targeting self-antigens. By exploring the…

BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures BioMavericks awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December Sandwich, UK, 6th December 2023 / Sciad Newswire / Discovery Park / BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures. Thirteen start-ups took part in the programme, including 3D Synthesis, Awen, Bing Bo…

Almac Discovery and Queen’s University Belfast have today announced a five-year project to develop a new Chemoproteomics Centre of Excellence for drug discovery.The multi-million-pound facility, which is jointly funded by Almac Discovery and a BBSRC Prosperity Partnership award, is a first of its kind in Northern Ireland and will be located at Queen’s.The project combines and harnesses the experience of industrial and academic experts to shine a new light on the way drug molecules could be used to treat disease, by using advanced mass spectrometry techniques to examine their effects on thousands of potential drug targets simultaneously, in disease relevant systems.This latest collaboration builds on a long-established relationship between Almac Discovery and Queen’s in biological research…

Company behind the successful life-sciences firm Moderna, Flagship Pioneering, has selected the UK for their first location outside of the US Announcement opens up new opportunities for life science start-ups and investments in the UK, complementing UK government’s plan to drive innovation in science and tech and boost the UK’s investment ecosystem New Memorandum of Understanding between Flagship and the Government cements the UK’s commitment to the sector, setting out how both can work together on clinical trials, potential UK manufacturing locations, and more Leading life sciences bioplatform company Flagship Pioneering has today (Tuesday 28 November) announced the UK as the home for its first base outside the US, paving the way for new scientific start-ups, discoveries and investments…

The Institute of Cancer Research, London, has been granted the highest national honour in UK further and higher education for its innovative work on breast cancer. The Queen’s Anniversary Prize recognises the ICR’s transformational breast cancer research programme, which has not only improved outcomes for patients in the UK but also benefitted global healthcare systems and economies. This is the second time the ICR has won a Queen’s Anniversary Prize in recent years, and it follows international recognition last year of the impact of the ICR’s breast cancer research in improving the outcomes for patients worldwide. The Queen’s Anniversary Prize, which “provides valuable external recognition to the institution as a whole”, acknowledges the significant contribution that the ICR has made towa…

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases BARCELONA, Spain and VANCOUVER, (WA), USA. November 14th, 2023 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.  The partnership repres…

First-of-its-kind device to seamlessly integrate augmented reality, AI-guided assessment, and tactile feedback to enhance the surgical skills and training experiences for general, gynecological, and laparoscopic surgeons CINCINNATI, OH – November 6, 2023 – Ethicon*, a Johnson & Johnson MedTech** company, today debuted an AI-powered Surgical Simulation Platform that supports skill development in current and future surgeons at the American Association of Gynecological Laparoscopists (AAGL) Global Congress. The technology ushers in a new era in surgical training by leveraging artificial intelligence (AI), and augmented reality (AR) powered trainings, real-time data, and tactical feedback. While demand for surgical training remains high, access to quality education can be challenging due…

Significant endorsement by the French government programme that promotes excellence in research and manufacturing of novel biotherapies Advances the Company’s ambitions for its Lakhesys™ platform Total company funding now over €30 Million Paris, France, October 24, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces it has been awarded a further €10.4 Million grant by the French government as part of its “Innovation in Biotherapies and Bioproduction” initiative. This initiative promotes excellence in research and manufacturing of novel biotherapies. The funds will be used to advance the development of Astraveus’ Lakhesys ™ platform. The grant was allocated follow…

Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB Edinburgh and Cambridge, UK, 29 September 2023 - Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB). Macomics’ operations are located in Edinburgh and Cambridge, two major hubs of life science research in the UK with R&D teams split 50:50 across both sites. To accommodate expansion and to be co-located in an entrepreneurial centre of scientific excellence, Macomic…

The 8-week programme offers in person training from industry leaders to build strong business foundations and prepare for investment  Finalists have the chance to win a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures  The winner will be announced at the GIANT Health conference on 5th December 2023  Sandwich, UK, 27th September 2023 / Sciad Newswire / Discovery Park / Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a busine…

Castres, France and Cambridge UK, 25 September 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of targets and use fragment and structure-based methods to identify small molecules that modulate their activity. This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories.  The research at Vernalis will be funded by Pierre F…

Awards distinguish innovations for delivering sustainability, efficiency and automation to researchers and therapy developers WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards, honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230908890343/en/ The three award-winning Thermo Fisher innovations include: The Thermo Scientific™ DynaSpin™ Single-use Centrifuge, recognized in the Anal…

The collaboration aims to identify disease-modifying interventions, with the goal of improving standards of care for people living with type 2 diabetes and cardiac fibrosis The Broad Institute of MIT and Harvard today announced a new research alliance with Novo Nordisk aimed at addressing critical unmet clinical needs in diabetes and cardiometabolic diseases. The collaboration will focus on advancing three programs over the next three years. Two programs aim to identify drug targets for clinically important subtypes of type 2 diabetes, which affects more than 37 million people in the United States alone, and one program aims to unravel the genetic roots of cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure…